REXTOVY FDA approval date

The FDA approved REXTOVY on 7 Mar 2023.

FDA approval date
7 Mar 2023

Drug identity has not yet been verified against registry records

Also recorded as NALOXONE HYDROCHLORIDE

Included trials

No linked trials for this drug yet. Browse all trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2023-03-07DayREXTOVYFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA208969", "applicant_as_listed_by_fda": "AMPHASTAR PHARMS INC", "brand_names": ["REXTOVY"], "active_ingredients": ["NALOXONE HYDROCHLORIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20230307", "matched_on": "drug record created from this FDA brand name"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026